These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 28795387

  • 1. Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.
    Yang XB, Chai XS, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Xiao SJ.
    Chin J Integr Med; 2018 Oct; 24(10):734-740. PubMed ID: 28795387
    [Abstract] [Full Text] [Related]

  • 2. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ.
    Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045
    [Abstract] [Full Text] [Related]

  • 3. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ.
    Complement Ther Med; 2014 Dec 10; 22(6):1010-8. PubMed ID: 25453521
    [Abstract] [Full Text] [Related]

  • 4. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
    Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A, North-East Japan Study Group.
    J Clin Oncol; 2020 Jan 10; 38(2):115-123. PubMed ID: 31682542
    [Abstract] [Full Text] [Related]

  • 5. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC.
    J Clin Oncol; 2016 Sep 20; 34(27):3258-66. PubMed ID: 27507876
    [Abstract] [Full Text] [Related]

  • 6. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
    Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K.
    J Clin Oncol; 2020 Jan 10; 38(2):124-136. PubMed ID: 31411950
    [Abstract] [Full Text] [Related]

  • 7. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z, Luo F, Zhang Y, Ma Y, Hong S, Yang Y, Fang W, Huang Y, Zhang L, Zhao H.
    Cancer Commun (Lond); 2019 Nov 07; 39(1):69. PubMed ID: 31699150
    [Abstract] [Full Text] [Related]

  • 8. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.
    Hou X, Li M, Wu G, Feng W, Su J, Jiang H, Jiang G, Chen J, Zhang B, You Z, Liu Q, Chen L.
    JAMA Netw Open; 2023 Feb 01; 6(2):e2255050. PubMed ID: 36753281
    [Abstract] [Full Text] [Related]

  • 9. Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.
    Zhang YQ, Jiang LJ, Jiang SX, Xu YF, Zhou BB, Huang GH, Liu DM, Wang Y, Fan WZ, Li JP, Wang B.
    J Vasc Interv Radiol; 2019 Jul 01; 30(7):1004-1012. PubMed ID: 31171399
    [Abstract] [Full Text] [Related]

  • 10. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    Cancer Chemother Pharmacol; 2015 Jun 01; 75(6):1229-36. PubMed ID: 25903122
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumira T, Matusura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K.
    Lung Cancer; 2015 Oct 01; 90(1):65-70. PubMed ID: 26238424
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.
    Lung Cancer; 2018 Oct 01; 124():65-70. PubMed ID: 30268482
    [Abstract] [Full Text] [Related]

  • 13. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
    Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group.
    Lancet Oncol; 2010 Feb 01; 11(2):121-8. PubMed ID: 20022809
    [Abstract] [Full Text] [Related]

  • 14. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H, Wang H, Xu L, Li M, Peng Y, Cai X, Feng Z, Ren W, Peng Z.
    Clin Lung Cancer; 2018 Nov 01; 19(6):484-492. PubMed ID: 30369426
    [Abstract] [Full Text] [Related]

  • 15. [Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
    Yang XB, Chen X, Wu WY, Long SQ, Chen SM, Han SW.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Nov 01; 36(11):1340-1344. PubMed ID: 30641628
    [Abstract] [Full Text] [Related]

  • 16. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, Zhou X, Sun J, Bai J, Ren B, Tian K, Xu Z, Xiao HL, Zhou Q, Han R, Chen H, Wang H, Yang Z, Gao C, Cai S, He Y.
    Clin Cancer Res; 2019 Dec 01; 25(23):6967-6975. PubMed ID: 31413010
    [Abstract] [Full Text] [Related]

  • 17. Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.
    An C, Zhang J, Chu H, Gu C, Xiao F, Zhu F, Lu R, Shi H, Zhang H, Yi X.
    Pathol Oncol Res; 2016 Oct 01; 22(4):763-8. PubMed ID: 27126186
    [Abstract] [Full Text] [Related]

  • 18. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    Liu K, Jiang G, Zhang A, Li Z, Jia J.
    BMC Cancer; 2020 Jan 30; 20(1):76. PubMed ID: 32000711
    [Abstract] [Full Text] [Related]

  • 19. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
    Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Dómine M, Reguart N, Guirado M, Sala MÁ, Vázquez-Estevez S, Caro RB, Drozdowskyj A, Verdú A, Karachaliou N, Molina-Vila MA, Rosell R, Spanish Lung Cancer Group (SLCG).
    Lung Cancer; 2020 Dec 30; 150():62-69. PubMed ID: 33070053
    [Abstract] [Full Text] [Related]

  • 20. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
    Lancet Oncol; 2015 Aug 30; 16(8):990-8. PubMed ID: 26159065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.